Major Pharmaceuticals Initiates Class II Recall for Chlorpromazine HCl Due to N-Nitroso Impurity
The Harvard Drug Group LLC dba Major Pharmaceuticals has initiated a Class II nationwide recall (D-0010-2026) for specific lots of Major ChlorproMAZINE Hydrochloride Tablets, USP, 25 mg. This voluntary action stems from critical CGMP deviations, specifically the detection of N-Nitroso Desmethyl Chlorpromazine exceeding recommended intake limits. This event signals heightened regulatory scrutiny on nitrosamine impurities, demanding immediate supply chain risk assessment and robust quality control from procurement and regulatory teams.
FDA Mandates Class II Recall: N-Nitroso Impurity Exceeds Limits in Chlorpromazine HCl
The U.S. Food and Drug Administration (FDA) has classified a voluntary recall initiated by The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories as Class II, underscoring a significant quality concern. This recall, identified as D-0010-2026, pertains to specific lots of Major ChlorproMAZINE Hydrochloride Tablets, USP, 25 mg, distributed nationwide. The affected products include 1256 blister packs, specifically Lots N01954 with an expiration date of November 30, 2025, and N02024 expiring on February 28, 2026. These tablets, packaged with NDC 0904-7130-61 and UPC (01)00309047130610, are prescribed for oral administration. The critical reason for this recall is attributed to Current Good Manufacturing Practice (CGMP) deviations, specifically the presence of N-Nitroso Desmethyl Chlorpromazine at levels exceeding the FDA's recommended intake limit. For procurement directors, this necessitates an immediate review of inventory and supply agreements for Chlorpromazine Hydrochloride, while regulatory affairs heads must assess the implications of such CGMP failures on product quality and patient safety, demanding prompt action to secure compliant supply.
Commercial Impact: Major Pharmaceuticals' Chlorpromazine HCl Supply Disruption
This Class II recall by Major Pharmaceuticals for ChlorproMAZINE Hydrochloride Tablets, USP, 25 mg, carries substantial commercial implications for the pharmaceutical supply chain. Chlorpromazine Hydrochloride is a critical antipsychotic medication, and any disruption in its availability can impact patient care. The recalling firm, The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories, based in La Vergne, TN, initiated this voluntary action on September 12, 2025, with the FDA classifying it on October 7, 2025. A Class II recall indicates that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. For business development executives, this event highlights the fragility of single-source reliance and the competitive opportunities arising from supplier instability. Supply chain VPs must immediately activate contingency plans to identify alternative sources and manage potential stock-outs, safeguarding continuity of supply for this essential molecule across the nationwide distribution network.
Market Exposure and Patient Safety: Assessing Chlorpromazine HCl Recall Implications
The nationwide distribution of the recalled Major ChlorproMAZINE Hydrochloride Tablets means that the market exposure is broad, impacting pharmacies, hospitals, and ultimately, patients across the United States. The presence of N-Nitroso Desmethyl Chlorpromazine above recommended limits is a significant concern, as nitrosamine compounds are classified as probable human carcinogens. This elevates the recall from a mere quality issue to a potential public health risk, albeit one where the adverse health consequences are considered temporary or reversible in a Class II scenario. For regulatory affairs teams, this underscores the imperative for robust impurity profiling and stringent quality control throughout the product lifecycle. Procurement directors must ensure that all affected lots (N01954, N02024) are promptly identified, quarantined, and returned, minimizing further patient exposure and mitigating legal and reputational risks. The event reinforces the need for continuous vigilance against known and emerging impurities in pharmaceutical products.
Strategic Sourcing for Chlorpromazine HCl: Identifying Qualified Alternative Manufacturers
Given the recall of ChlorproMAZINE Hydrochloride Tablets by Major Pharmaceuticals, procurement teams must urgently re-evaluate their sourcing strategies for this critical active pharmaceutical ingredient (API) and finished dosage form. While specific alternative suppliers are not detailed in our current intelligence, the market for Chlorpromazine Hydrochloride includes several established manufacturers globally. Supply chain VPs should prioritize identifying and rigorously qualifying new or existing alternative suppliers with a proven track record of CGMP compliance and robust nitrosamine risk management programs. This involves comprehensive audits, review of impurity profiles, and validation of manufacturing processes to ensure compliance with FDA standards. Diversifying the supplier base geographically can also enhance supply chain resilience against localized disruptions. The qualification timeline for a new supplier can be extensive, often spanning 12-24 months, making proactive engagement critical to prevent prolonged supply gaps and maintain market access for essential medications.
Nitrosamine Contamination: A Persistent Regulatory Challenge for the Pharmaceutical Industry
The detection of N-Nitroso Desmethyl Chlorpromazine exceeding intake limits in Major Pharmaceuticals' product is not an isolated incident but reflects a broader, persistent challenge within the global pharmaceutical industry regarding nitrosamine contamination. This issue has led to numerous recalls across various drug classes in recent years, prompting intensified regulatory scrutiny from agencies like the FDA. The root cause often traces back to CGMP deviations, including issues with raw material quality, manufacturing processes, or packaging interactions. While our knowledge graph highlights other recent Class II recalls, such as Essential Wellness Pharma's progesterone injection for sterility, and FDA hearings impacting companies like Amgen, these events collectively underscore an environment of heightened regulatory oversight on all aspects of pharmaceutical quality and safety. Regulatory affairs heads must proactively implement enhanced risk assessments, develop robust control strategies, and update quality management systems to address potential nitrosamine formation pathways across their entire product portfolios, ensuring compliance and safeguarding product integrity.
Post-Recall Remediation: Major Pharmaceuticals' Path to Restored Compliance
As an ongoing Class II recall, Major Pharmaceuticals faces significant remediation efforts to address the identified CGMP deviations and the presence of N-Nitroso Desmethyl Chlorpromazine. The firm is expected to conduct a thorough root cause analysis to understand how the impurity formed and why it exceeded recommended limits. This will necessitate implementing comprehensive Corrective and Preventive Actions (CAPA) across its manufacturing and quality control systems. Regulatory affairs teams will be closely monitoring Major Pharmaceuticals' response, as the FDA will require detailed documentation of these actions and their effectiveness. Failure to adequately remediate could lead to further regulatory actions, including potential Warning Letters or even facility closures, impacting future product approvals and market access. Business development executives should track the company's progress, as a successful remediation could restore market confidence, while prolonged issues might open avenues for competitors to capture market share for Chlorpromazine Hydrochloride and related products. This situation serves as a critical reminder for all industry players to continuously strengthen their quality assurance frameworks.